UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Changes to aspects of ongoing randomised controlled trials with fixed designs

Trials, 2020-06, Vol.21 (1), p.457-457, Article 457

2020

Volltextzugriff (PDF)

SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancer

EClinicalMedicine, 2023-12, Vol.66, p.102346-102346, Article 102346

2023

Volltextzugriff (PDF)

Early to Middle Miocene rotational tectonics of the Ou Backbone Range, northeast Japan

The island arc, 2015-09, Vol.24 (3), p.288-300

2015

Volltextzugriff (PDF)

How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach

British journal of dermatology (1951), 2023-10, Vol.189 (Suppl 1), p.i3-i10

2023

Volltextzugriff (PDF)

Effects of [ 177 Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5045-5045

2023

Volltextzugriff (PDF)

PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177 Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.10-10

2022

Volltextzugriff (PDF)

Evolution: Phase II study of radionuclide 177 Lu-PSMA-617 therapy versus 177 Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS271-TPS271

2023

Volltextzugriff (PDF)

DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS396-TPS396

2023

Volltextzugriff (PDF)

Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14576-e14576

2019

Volltextzugriff (PDF)

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

The lancet oncology, 2024-05, Vol.25 (5), p.563-571

2024

Volltextzugriff (PDF)

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5102-TPS5102

2023

Volltextzugriff (PDF)

INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS366-TPS366

2022

Volltextzugriff (PDF)

What is normal bladder neck anatomy?

International Urogynecology Journal, 2016-06, Vol.27 (6), p.945-950

2016

Volltextzugriff (PDF)

Fear of Failure: Friend or Foe?

Australian psychologist, 2003-03, Vol.38 (1), p.31-38

2003

Volltextzugriff (PDF)

SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1505-1505

2023

Volltextzugriff (PDF)

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5103-TPS5103

2022

Volltextzugriff (PDF)

Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 177 LuPSMA-617 and NOX66 (LuPIN)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.166-166

2022

Volltextzugriff (PDF)

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS205-TPS205

2022

Volltextzugriff (PDF)

Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.328-328

2024

Volltextzugriff (PDF)

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS284-TPS284

2022

Volltextzugriff (PDF)

SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.84-84

2023

Volltextzugriff (PDF)

Adding mitomycin (MM) to bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non–muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4617-TPS4617

2023

Volltextzugriff (PDF)

SUB-urothelial durvalumab injection: 1 (SUBDUE-1)—Results from the first nine urothelial cancer patients using a dose-escalation schedule

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.483-483

2022

Volltextzugriff (PDF)

Estimating survival time in older adults receiving chemotherapy for advanced cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e23017-e23017

2019

Volltextzugriff (PDF)

Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.151-151

2024

Volltextzugriff (PDF)

1 – 25 von 3.719

Suche als RSS-Feed

Aktive Filter

PublikationsformArtikel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.577)
Mit Volltextzugriff
(3.120)

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.607)
Life Sciences & Biomedicine
(2.158)
Humans
(1.773)
Female
(920)
Male
(917)
Middle Aged
(649)
Aged
(557)
Adult
(525)
Biological And Medical Sciences
(396)
Animals
(353)
Medical Sciences
(337)
General & Internal Medicine
(323)
Risk Factors
(272)
Physical Sciences
(269)
Patients
(264)
Treatment Outcome
(246)
Science & Technology - Other Topics
(233)
Medicine, General & Internal
(229)
Surgery
(226)
Multidisciplinary Sciences
(216)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(107)
Blood
(71)
The New England Journal Of Medicine
(64)
Plos One
(58)
Journal Of Medicinal Chemistry
(53)
The Lancet
(50)
Nature
(48)
Nature Genetics
(48)
Nature Communications
(47)
Stroke
(45)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(12)
... seit 90 Tagen
(47)

Menü

Weitere Dienste

Einstellungen

Changes to aspects of ongoing randomised controlled trials with fixed designs

SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancer

Early to Middle Miocene rotational tectonics of the Ou Backbone Range, northeast Japan

How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach

Effects of [ 177 Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis

PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177 Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)

Evolution: Phase II study of radionuclide 177 Lu-PSMA-617 therapy versus 177 Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)

DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer

Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)

INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC)

What is normal bladder neck anatomy?

Fear of Failure: Friend or Foe?

SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 177 LuPSMA-617 and NOX66 (LuPIN)

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa)

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors

Adding mitomycin (MM) to bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non–muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301

SUB-urothelial durvalumab injection: 1 (SUBDUE-1)—Results from the first nine urothelial cancer patients using a dose-escalation schedule

Estimating survival time in older adults receiving chemotherapy for advanced cancer

Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304)

Aktive Filter

Suchergebnisse filtern